Posted by Michael Wonder on 29 Jul 2025
PTC Therapeutics announces FDA approval of Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria
28 July 2025 - Broad labelling inclusive of all disease subtypes for individuals 1 month of age and older.
PTC Therapeutics announced today that the US FDA has approved Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria.
